July 28, 2016

Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update

Three months ended June 30, Continued growth in active patients with 891 active patients at June 30, 2016, an increase of 110 percent from second quarter 2015, and 12 percent from first quarter 2016 Second quarter 2016 reported revenues of $17.9 million, reflecting 174 percent growth… Read More
learn more
July 28, 2016

Novocure to Host Research and Development Day on Dec. 12, 2016

July 28, 2016 06:25 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST… Read More
learn more
July 28, 2016

Novocure to Host Research and Development Day on Dec. 12, 2016

July 28, 2016 06:25 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST… Read More
learn more
July 28, 2016

Novocure to Host Research and Development Day on Dec. 12, 2016

July 28, 2016 06:25 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) announced today that the company will hold a research and development day for analysts and investors on Monday, Dec. 12, 2016, from 1 to 4 p.m. EST… Read More
learn more
July 28, 2016

Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update

Three months ended June 30, Continued growth in active patients with 891 active patients at June 30, 2016, an increase of 110 percent from second quarter 2015, and 12 percent from first quarter 2016 Second quarter 2016 reported revenues of $17.9 million, reflecting 174 percent growth… Read More
learn more
July 28, 2016

Novocure Reports Second Quarter 2016 Financial Results and Provides Company Update

Three months ended June 30, Continued growth in active patients with 891 active patients at June 30, 2016, an increase of 110 percent from second quarter 2015, and 12 percent from first quarter 2016 Second quarter 2016 reported revenues of $17.9 million, reflecting 174 percent growth… Read More
learn more
July 26, 2016

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate July 26, 2016 09:46 AM Eastern Daylight Time ST. HELIER,… Read More
learn more
July 26, 2016

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate July 26, 2016 09:46 AM Eastern Daylight Time ST. HELIER,… Read More
learn more
July 26, 2016

NCCN Guidelines Recommend Optune as a Standard Treatment Option for Newly Diagnosed Glioblastoma

Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate Optune designated as category 2A treatment for newly diagnosed GBM, indicating uniform consensus that the intervention is appropriate July 26, 2016 09:46 AM Eastern Daylight Time ST. HELIER,… Read More
learn more
July 13, 2016

Novocure Receives FDA Approval for Second Generation Optune System

Second generation Optune system is less than half the weight and size of first generation Optune system New system aims to make Optune therapy even easier for glioblastoma (GBM) patients Novocure’s new system aims to make Optune therapy even easier for… Read More
learn more